[go: up one dir, main page]

MX2024011036A - Inhibidores duales de lsd1/hdac. - Google Patents

Inhibidores duales de lsd1/hdac.

Info

Publication number
MX2024011036A
MX2024011036A MX2024011036A MX2024011036A MX2024011036A MX 2024011036 A MX2024011036 A MX 2024011036A MX 2024011036 A MX2024011036 A MX 2024011036A MX 2024011036 A MX2024011036 A MX 2024011036A MX 2024011036 A MX2024011036 A MX 2024011036A
Authority
MX
Mexico
Prior art keywords
formula
enzymes
compounds
lsd1
diastereomers
Prior art date
Application number
MX2024011036A
Other languages
English (en)
Inventor
Dhanalakshmi Sivanandhan
Luca Rastelli
Naveen Sadhu
Chandru Gajendran
Rajagopal Sridharan
Original Assignee
Jubilant Epicore LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jubilant Epicore LLC filed Critical Jubilant Epicore LLC
Publication of MX2024011036A publication Critical patent/MX2024011036A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgación proporciona un compuesto de la Fórmula (I), sus análogos, formas tautoméricas, estereoisómeros, enantiómeros, diastereómeros y sales farmacéuticamente aceptables del mismo. La presente divulgación también proporciona un proceso para preparar los compuestos de la Fórmula (I), sus análogos, formas tautoméricas, estereoisómeros, enantiómeros, diastereómeros y sales farmacéuticamente aceptables de los mismos. Los compuestos de la Fórmula (I) modulan MYC o coREST, en un sujeto en necesidad del mismo. Los compuestos de la Fórmula (I) inhiben las enzimas HDAC o las enzimas LSD1, o tanto las enzimas HDAC como las enzimas LSD1. El compuesto de la Fórmula (I) es un agente modulador epigenético con un mecanismo de acción novedoso que se dirige a la amplificación de MYC en múltiples tipos de tumores neuroendocrinos.
MX2024011036A 2022-03-10 2023-03-10 Inhibidores duales de lsd1/hdac. MX2024011036A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN202241013165 2022-03-10
US202263368342P 2022-07-13 2022-07-13
IN202241057045 2022-10-04
PCT/IN2023/050233 WO2023170715A1 (en) 2022-03-10 2023-03-10 Dual lsd1/hdac inhibitors

Publications (1)

Publication Number Publication Date
MX2024011036A true MX2024011036A (es) 2024-09-18

Family

ID=87936318

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011036A MX2024011036A (es) 2022-03-10 2023-03-10 Inhibidores duales de lsd1/hdac.

Country Status (7)

Country Link
EP (1) EP4489735A1 (es)
JP (1) JP2025507598A (es)
KR (1) KR20240164498A (es)
AU (1) AU2023232568A1 (es)
IL (1) IL315081A (es)
MX (1) MX2024011036A (es)
WO (1) WO2023170715A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3455204A1 (en) * 2016-05-09 2019-03-20 Jubilant Biosys Ltd. Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors

Also Published As

Publication number Publication date
WO2023170715A1 (en) 2023-09-14
KR20240164498A (ko) 2024-11-19
AU2023232568A1 (en) 2024-08-15
JP2025507598A (ja) 2025-03-21
EP4489735A1 (en) 2025-01-15
IL315081A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
PH12021552805A1 (en) Cdk inhibitors
MX2024000230A (es) Inhibidores de cdk2.
ZA202104112B (en) 15-pgdh inhibitor
MA62912A1 (fr) Inhibition de la protéase 1 spécifique de l'ubiquitine (usp1)
EP1322619A4 (en) ISOQUINOLINONE AS POTASSIC CHANNEL INHIBITORS
MX2023010125A (es) Inhibidores del sarcomero cardiaco.
PH12022553498A1 (en) Novel acid secretion inhibitor and use thereof
IL148932A0 (en) INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
MX2023008296A (es) Compuestos de isoindolinona.
MX2023007443A (es) Composiciones para reducir la emision de metano, metodos para mejorar la eficiencia metabolica de animales rumiantes y administracion de inhibidores de la metanogenesis.
TW200637539A (en) CTGF inhibitors
SA522431429B1 (ar) Sting مركبات كبيرة الحلقات كمساعِدات وطرق واستخداماتها
WO2024026433A3 (en) Novel dpp1 inhibitors and uses thereof
MX2022006653A (es) Compuestos para modular la actividad de fxr y usos de los mismos.
MX2024008910A (es) Farmaceutico para tratamiento de infeccion de nuevo coronavirus.
MX2024011036A (es) Inhibidores duales de lsd1/hdac.
MX2021000468A (es) Inhibidores de la histona desacetilasa.
MX2024001829A (es) Derivado de triazol sustituido, metodo de preparacion del mismo, composicion farmaceutica del mismo y uso del mismo.
WO2021205388A3 (en) An improved process for the preparation of semaglutide side chain
MX2023015245A (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2.
EP4406929A3 (en) Mixtures comprising a solid carrier comprising an urease inhibitor and a further solid carrier comprising a nitrification inhibitor
MX2024005066A (es) Compuestos de cd73.
MX2023004492A (es) Compuestos de triazolopiridinilo como inhibidores de cinasas.
CR20220551A (es) Procesos para la preparación de un inhibidor de cinasa
MX2023000936A (es) Proceso para preparar un compuesto de isoxazolina e intermedio del mismo.